EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial

Vincenzo Nasca, Natalie Prinzi, Jorgelina Coppa, Michele Prisciandaro, Simone Oldani, Filippo Ghelardi, Elena Conca, Iolanda Capone, Adele Busico, Federica Perrone, Elena Tamborini, Giovanna Sabella und 11 weitere

European Journal of Cancer · 2024-09 · 209 · 114276

DOI: 10.1016/j.ejca.2024.114276 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2024-09. Verfasst von Vincenzo Nasca und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fondazione IRCCS Istituto Tumori Milano, Milan, Italy. Hauptthemen laut MEDLINE: Sunitinib, Pheochromocytoma, Paraganglioma, Adrenal Gland Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SunitinibPheochromocytomaParagangliomaAdrenal Gland NeoplasmsHumansFemaleMaleMiddle AgedAgedAdultProspective StudiesAntineoplastic AgentsProgression-Free Survival

Stichwörter der Autor:innen

ParagangliomaPheocromocytomaSunitinibTKI

Substanzen

SunitinibAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Oncology, Fondazione IRCCS Istituto Tumori Milano, Milan, Italy.
  • Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Diagnostic Pathology and Laboratory Medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Radiology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Sarcoma and Rare Tumors Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, Naples, Italy; ENETs Center of Excellence, Naples, Italy.
  • Department of Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, ENETS Center of Excellence, Milan, Italy.

Förderung

  • Pfizer

Zitieren

APA

Nasca, V., Prinzi, N., Coppa, J., Prisciandaro, M., Oldani, S., Ghelardi, F., Conca, E., Capone, I., Busico, A., Perrone, F., Tamborini, E., Sabella, G., Greco, G., Greco, F. G., Tafuto, S., Procopio, G., Morano, F., Niger, M., Maccauro, M., …, & Pusceddu, S. (2024). Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial. European Journal of Cancer, 209, 114276. https://doi.org/10.1016/j.ejca.2024.114276

Vancouver

Nasca V, Prinzi N, Coppa J, Prisciandaro M, Oldani S, Ghelardi F, et al. Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial. European Journal of Cancer. 2024;209:114276. doi:10.1016/j.ejca.2024.114276

BibTeX
@article{Nasca2024,
  author = {Nasca, Vincenzo and Prinzi, Natalie and Coppa, Jorgelina and Prisciandaro, Michele and Oldani, Simone and Ghelardi, Filippo and Conca, Elena and Capone, Iolanda and Busico, Adele and Perrone, Federica and Tamborini, Elena and Sabella, Giovanna and Greco, Giorgio and Greco, Francesca Gabriella and Tafuto, Salvatore and Procopio, Giuseppe and Morano, Federica and Niger, Monica and Maccauro, Marco and Milione, Massimo and de Braud, Filippo and Pietrantonio, Filippo and Pusceddu, Sara},
  title = {Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial},
  journal = {European Journal of Cancer},
  year = {2024},
  volume = {209},
  pages = {114276},
  doi = {10.1016/j.ejca.2024.114276}
}
Kostenlos starten →